- Home
- BEAM vs SAND Comparison
BEAM vs SAND Comparison
Compare BEAM & SAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- SAND
- Stock Information
- Founded
- BEAM 2017
- SAND 2007
- Country
- BEAM United States
- SAND Canada
- Employees
- BEAM N/A
- SAND N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- SAND
- Sector
- BEAM Health Care
- SAND
- Exchange
- BEAM Nasdaq
- SAND NYSE
- Market Cap
- BEAM 1.6B
- SAND 2.4B
- IPO Year
- BEAM 2020
- SAND N/A
- Fundamental
- Price
- BEAM $19.88
- SAND $9.43
- Analyst Decision
- BEAM Strong Buy
- SAND Buy
- Analyst Count
- BEAM 11
- SAND 4
- Target Price
- BEAM $48.90
- SAND $9.13
- AVG Volume (30 Days)
- BEAM 2.0M
- SAND 5.0M
- Earning Date
- BEAM 08-05-2025
- SAND 07-31-2025
- Dividend Yield
- BEAM N/A
- SAND 0.67%
- EPS Growth
- BEAM N/A
- SAND 32.83
- EPS
- BEAM N/A
- SAND 0.10
- Revenue
- BEAM $63,578,000.00
- SAND $183,537,000.00
- Revenue This Year
- BEAM N/A
- SAND $17.55
- Revenue Next Year
- BEAM $8.82
- SAND $10.62
- P/E Ratio
- BEAM N/A
- SAND $96.49
- Revenue Growth
- BEAM N/A
- SAND 2.84
- 52 Week Low
- BEAM $13.53
- SAND $4.92
- 52 Week High
- BEAM $35.25
- SAND $9.68
- Technical
- Relative Strength Index (RSI)
- BEAM 67.72
- SAND 59.49
- Support Level
- BEAM $16.59
- SAND $8.95
- Resistance Level
- BEAM $17.38
- SAND $9.59
- Average True Range (ATR)
- BEAM 1.09
- SAND 0.24
- MACD
- BEAM 0.24
- SAND -0.02
- Stochastic Oscillator
- BEAM 93.78
- SAND 77.40
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About SAND SANDSTORM GOLD LIMITED
Sandstorm Gold Ltd provides financing to companies engaged in gold mining through the gold stream and royalty. Geographically, the company has operational footprints in North America, South & Central America, Africa, and Asia & Australia. The firm's royalties include Hod Maden, Santa Elena, Chapada, Platreef, Greenstone, and Cerro Moro.